Back to search
FDAFDA · Food and drugs·Recall number D-1288-2015

Absorica (isotretinoin) Capsules, 25 mg, Packaged in 3 x 10 Count Blister Cards/Box, Rx Only. Manufactured for: RANBAXY LABORATORIES, INC Jacksonville, FL 32257 USA. NDC: 10631-133-31.

Published August 12, 2015 · Recall initiated: June 26, 2015

Summary

FDA records drug Class II recall D-1288-2015, published August 12, 2015 and initiated June 26, 2015. Recalling firm: Ranbaxy Inc.; Status: Terminated; Reported quantity: 9,229 Boxes; Lot: Lot #:14H04AA, Expiry: 02/28/2017. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Incorrect/Undeclared Excipients: Product contains undeclared FD&C Yellow No. 5 in the capsule shell.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Ranbaxy Inc.
Distributor
Nationwide
Lot
Lot #:14H04AA, Expiry: 02/28/2017.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Absorica (isotretinoin) Capsules, 25 mg, Packaged in 3 x 10 Count Blister Cards/Box, Rx Only. Manufactured for: RANBAXY LABORATORIES, INC Jacksonville, FL 32257 USA. NDC: 10631-133-31. recalled?

Yes. FDA published recall D-1288-2015 on August 12, 2015. Reported hazard: Incorrect/Undeclared Excipients: Product contains undeclared FD&C Yellow No. 5 in the capsule shell.

What should I do if I have this product?

Voluntary: Firm initiated · Letter